19 October-1 December 2020
The 51st Union World Conference On Lung Health
REGISTER NOW

Sessions

All Sessions
keyboard_arrow_down
keyboard_arrow_down Show filters keyboard_arrow_up Hide filters
  • All Tracks
  • Community Connect
  • Channel 1
  • Channel 2
  • Channel 3
  • Channel 4
  • Channel 5
  • Channel 6
  • Channel 7
  • E-posters
  • Workshops
E-posters
EP10-Overcoming barriers in the contact cascade of care
event_note
Loading...
query_builder 10:00 - 11:00 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel E-poster session
mic English
EP10-Overcoming barriers in the contact cascade of care
*Please scroll down for more information*
All E-posters are accessible via the "E-posters" section of the conference platform until 30 November.

EP10-187-21-A missed opportunity: active contact investigation of diagnosed TB patients in NigeriaPeople who have been in close contact with bacteriologically confirmed pulmonary tuberculosis (TB) patients constitute a high-risk group for developing TB disease. Active household contact investigation of index TB patients demonstrates a great opportunity to increase a diverse pool of human resources, capacity to diagnosis and to notify additional TB cases.
Sani Useni

EP10-188-21-Risk of developing active multidrug-resistant TB among contacts in Taiwan, 2016-2018Identifying at-risk contacts, who have been exposed to a multidrug-resistant tuberculosis (MDR-TB) index patient, to see if they develop active disease would help advancing prevention of MDR-TB in Taiwan. In addition, active follow-up and prioritising those household or IGRA-positive contacts for latent TB treatment may further decline the incidence of MDR-TB. 
Pin Hui Lee

EP10-189-21-Utility of interferon gamma/tumor necrosis factor alpha FluoroSpot assay in differentiation between active TB and latent TB infection: a pilot studyWe aimed to provide a highly sensitive and practical auxiliary method for tuberculosis (TB) differential diagnosis. In this abstract, we demonstrated the diagnostic accuracy of the interferon gamma/tumor necrosis factor alpha (IFN-γ/TNF-α ) FluoroSpot assay for differentiating active TB from latent TB infection. 
Ziyue Zhou

EP10-190-21-Results of management latent TB infection in Quang Nam province, Viet Nam, 2017-2018Results of the management of latent tuberculosis (TB) infection during the period of 2017-2018 in Quang Nam province, Viet Nam. Interventions have shown to be effective in increasing the ability to identify, screen TB and treat latent TB infection among household contacts of TB patients.
LV Vinh

EP10-192-21-Effectiveness of contact tracing intervention for improving TB case detection in NigeriaSystematic investigation of contacts of index TB cases for active disease has remained a priority active case finding strategy. Stakeholders for tuberculosis (TB) control need to apply the right strategy, job aid, tools and training for health workers to help standardise TB information and empower communities with the right TB knowledge
Chidubem Ogbudebe

EP10-193-21-Dilemma in contact investigation: to expand or notContact investigation as a part of Dutch tuberculosis (TB) policy aims for early case detection, treatment and prevention of TB transmission. Risk assessment forms a basic approach to the organisation of contact investigation.
Sophie Toumanian

EP10-194-21-Piloting a shortened regimen for the treatment of latent TB infection in two provinces of Viet NamIn 2019, Friends for International TB Relief, together with the Viet Nam National TB Programme, implemented community-based tuberculosis (TB) case finding campaigns with integrated latent TB infection testing and treatment using a shortened regimen in two provinces of Viet Nam. We herein describe the results of these activities.
Thuy Thu Thi Dong

EP10-195-21-Prevalence of latent TB infection and predictive factors among working-age population in urban and rural area of Northern Guangdong, China: a cross-sectional studyChina has one of the highest burdens of latent tuberculosis (TB) infection (LTBI). Studies, which mainly focused on high-risk population, observed LTBI prevalence ranging from 9% up to 70%. The goal of this study was to describe LTBI burden in the general population, especially in those of working age, and determine its associated factors.
Fangjing ZHOU

EP10-196-21-Impact of civil society advocacy on the introduction of TB LAM testing in PEPFAR-eligible countriesUptake of tuberculosis (TB) LAM testing in high TB and HIV burden countries has been limited despite a demonstrated mortality benefit among people with advanced HIV. We reviewed FY2018 and FY2019 PEPFAR country operational plans to evaluate the impact of advocacy on TB LAM uptake in PEPFAR-eligible countries.
David Branigan

Loading...
E-posters
EP07-Improving TB care in children
event_note
Loading...
query_builder 10:00 - 11:00 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel E-poster session
mic English
EP07-Improving TB care in children
*Please scroll down for more information*
All E-posters are accessible via the "E-posters" section of the conference platform until 30 November.

EP07-159-21-Detecting and preventing paediatric TB through systematic household contact investigations in nine sub-Saharan countriesWe describe yields in tuberculosis (TB) detection and TB preventive therapy cascades - from screening to treatment completion - obtained during an intervention supporting systematic household contact investigation of paediatric TB index cases across nine sub-Saharan countries.
Jean-Francois Lemaire

EP07-160-21-Paediatric TB detection and treatment cascade in nine sub-Saharan countries following the CaP-TB interventionWe prospectively documented retention in the paediatric tuberculosis (TB) care cascade - from screening to treatment outcomes - during a comprehensive intervention, including paediatric specific systematic symptoms screening in health facilities, increased access to Xpert MTB/RIF testing, intensified household contact investigation and treatment of drug-sensitive TB with child-friendly formulations across nine sub-Saharan countries.
Shirin Kakayeva

EP07-161-21-Increasing paediatric TB detection and treatment in private health sector in IndiaWe share findings from the intervention on integrating comprehensive paediatric tuberculosis (TB) care cascade among private healthcare facilities in India. This includes evidence from intensified case finding activities in private facilities, enhancing their access to government’s free Xpert MTB/RIF diagnostics and WHO approved child-friendly fixed dose combination (FDC) dispersible drugs.
Karun Sandeep Veesa

EP07-162-21-Training physicians in India to interpret paediatric chest radiographs according to World Health Organization research methodologyChest radiography is the standard for diagnosing paediatric lower respiratory infections in low- and middle-income countries. Research in India required training local physicians to interpret chest radiographs following an updated World Health Organization interpretation method. We described the methodology for training Indian physicians and evaluated the training’s effectiveness.
Eric D McCollum

EP07-163-21-Care cascade of contact screening and preventive therapy among children under five in high-burden districts of NepalContact screening and provision of preventive therapy for under 5s as one intervention to prevent childhood TB in 38 high-burden districts of Nepal from 2017. Care cascade constructed in this paper focuses on contract tracing done during the period of March 2018-Dec 2019.
Suvesh Kumar Shrestha

EP07-164-21-Paediatric latent TB infection cascade of care from the TB and Leprosy Free Majuro community mass screening projectTB and Leprosy Free Majuro was a tuberculosis/latent tuberculosis infection (TB/LTBI) mass screening campaign implemented by the Republic of the Marshall Islands' Ministry of Health, on Majuro Atoll, from June to November 2018. It offered screening and treatment for LTBI in children 0-14 years old with varying success depending on age cohort.
Rachel Dwilow

EP07-165-21-Improvement of screening for childhood TB in Senegal coupled with screening for malnutrition: pilot study in the health districts of Thiès and Tivaouane, SénégalWe carried out operational research on the integration of the two tuberculosis (TB) and malnutrition control programmes to improve the screening of these diseases in children aged 0 to 14. This research developed by OMS/TDR shows that it can help the programme to improve the screening of childhood TB in Senegal.
Nafissatou Oumar Toure

EP07-166-21-Barriers to uptake of isoniazid preventive therapy among eligible child household contacts of TB patients in Southern NigeriaThis research explores the barriers to the uptake of isoniazid preventive therapy among eligible child contacts (under 6 years of age) of TB patients in six states of Southern Nigeria. Study findings highlight both patients and health systems factors.
Chukwuka Alphonsus

EP07-167-21-The state of paediatric, rifampicin-resistant TB in Khayelitsha, South AfricaOutcomes for paediatrics who receive rifampicin-resistant TB (RR-TB) treatment are excellent. Despite universal access to Xpert in South Africa, the frequency of paediatric cases detected has not increased, suggesting that diagnosis of RR-TB in paediatrics remains a challenge. Efforts to improve case detection, contact assessment and appropriate treatment initiation are urgently needed.
Johnny Daniels

Loading...
Channel 7
SP-02-Tests for the detection of TB infection - tuberculin skin test vs interferon-gamma release assays
event_note
Loading...
query_builder 11:00 - 12:20 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Symposium
mic English
SP-02-Tests for the detection of TB infection - tuberculin skin test vs interferon-gamma release assays
*Please scroll down for more information*
There is no gold standard method for diagnosing tuberculosis (TB) infection. The World Health Organization (WHO) currently recommends a tuberculin skin test (TST) or an interferon-gamma release assay (IGRA) to test for TB infection to identify candidates for TB preventive treatment. This session reviews current WHO guidelines on who to test and critically reviews the related programmatic and implementation considerations. The pros and cons of current TB infection tests are discussed, including issues of supply. Finally, status of development and potential advantages and disadvantage of future tests for TB infection are addressed.

11:00 - 11:05: Introduction

11:05 - 11:15: Evidence and policy recommendations for testing for TB infection before TB preventive treatmentTuberculosis preventive treatment (TPT) should be selectively targeted to population groups at highest risk of progression to active disease. World Health Organization (WHO) guidelines strongly recommend TPT for adults and adolescents living with HIV and for children aged < 5 years who are household contacts of people with bacteriologically-confirmed pulmonary TB, if active TB is excluded. These groups should be given TPT even if TB infection testing is unavailable. However, for household contacts aged ˃= 5 years, confirmation of TB infection using IGRA or TST before starting TPT is desirable. Finally, systematic testing for TB infection and TPT is recommended for people who are initiating anti-tumor necrosis factor treatment, receiving dialysis, preparing for an organ or haematological transplant, or who have silicosis. It may also be done for prisoners, health workers, immigrants from countries with a high TB burden, homeless people and people who use drugs. In this presentation the WHO recommendations and underlying evidence are discussed.
Yohhei Hamada

11:15 - 11:25: Who to test: programmatic and implementation considerationsPartly as a result of testing availability and limitations in their accuracy, tuberculosis (TB) infection tests are not required prior to start of TB preventive therapy (TPT) in priority risk groups: people living with HIV (PLHIV) and household contacts aged less than 5 years. For other at-risk populations (household contacts 5 years and older and other high-risk groups), TB infection tests are generally recommended to identify those who would benefit most from treatment and to avoid unnecessary medication. However, implementation of TB infection tests is fraught with difficulties ranging from high cost, cold chain requirements (TST), short supply of quality-assured TST, to inadequate laboratory setup in undertaking high volumes of IGRA testing in decentralised settings where people need them. In this session the pros and cons of the requirement to test household contacts and HIV negative individuals before starting TPT are discussed, including risk-benefit considerations and programmatic implications.
Dick Menzies

11:25 - 11:35: TST vs IGRACurrently available tests for tuberculosis infection have major limitations. They have poor predictive value for development of active TB and do not indicate whether treatment of TB infection has been successful, which means that most people who have successfully completed what is considered an adequate course of preventive treatment will usually continue to have a positive test. IGRA needs sophisticated laboratory infrastructure and technical expertise as well as expensive equipment. TST is considered less resource intensive than IGRA but it requires a cold chain, two healthcare visits and needs training for intradermal injection and reading and interpretation and its quality control is a challenge. In the following presentations we present the true differences in the performance of these tests, but also the different roles these tests have in different settings.
Daniela Cirillo

11:35 - 11:45: Supplies of TST/IGRAGovernments and donors should invest and build health system capacity (human resources, logistics and supply chain and monitoring and evaluation) for TST and/or IGRA to avoid unnecessary TB preventive therapy, related harms and to improve acceptance. For TST this requires ensuring the availability and supply of tuberculin in cold chain as well as syringes, needles and consumables. IGRA tests have many infrastructural requirements (e.g. capacity of the laboratory system to conduct IGRA, including phlebotomy, processing of blood specimen, incubation and enzyme-linked immunsorbent assay (ELISA) reading) and are costly (unit test costs as well as need for laboratory infrastructure and laboratory personnel), making routine programmatic use in most low-and middle-income countries challenging. Supply of appropriate reagents and testing tubes for IGRA need to be ensured. However, having this capacity in place will also enable rapid adoption of any new TB infection test endorsed for programmatic use in future.
Brenda Waning

11:45 - 11:55: Future tests for TB infectionNew versions of TST and IGRA are expected to be launched in the immediate future, all using recombinant ESAT6-CFP10 antigens (C-Tb (Serum Institute of India, India), Diaskin Test (Generium, Russian Federation) and ESAT6-CFP10 test (Anhui Zhifei Longcom, China)) as well as point of care IGRA tests (Quantiferon Access and Standard E and F TB-feron tests from SD biosensor and the Advansure TB-IGRA test from LG Chem). Qiagen and SD Biosensor have both developed a simplified version of the IGRA that can be operated in peripheral facilities without laboratory infrastructures. These tests offer an incremental gain in ease of use or cost, or other operational aspects, but are not expected to provide major advantages in diagnostic test accuracy or predictive ability. In this presentation the status of development of new tests is presented, potential advantages and disadvantage of future tests for tuberculosis infection are discussed and remaining gaps are identified.
Morten Ruhwald

11:55 - 12:20: Q&A session

Loading...
Channel 7
SP-07-Towards new TB vaccines: progress and considerations for introduction
event_note
Loading...
query_builder 12:30 - 13:50 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Symposium
mic English
SP-07-Towards new TB vaccines: progress and considerations for introduction
*Please scroll down for more information*
The World Health Organization End TB strategy aims to end the tuberculosis (TB) epidemic by 2035. A new TB vaccine that is safe, affordable and effective in providing protection against all forms of TB in adolescents and adults is critical for rapidly reducing disease incidence and mortality. There are currently promising candidates in the clinical pipeline. However, accelerating progress requires a globally coordinated plan to efficiently streamline the complex approaches to testing and the introduction of new vaccines. This symposium aims to discuss current evidence around the full benefits new vaccines offer, as well as venues needed to accelerate development and to facilitate programmatic implementation.

12:30 - 12:35: Introduction

12:35 - 12:47: World Health Organization preferred product characteristics for preventive and therapeutic vaccinesThis presentation outlines the World Health Organization's (WHO’s) preferred and minimal product characteristics (PPCs) for both preventive and therapeutic vaccines. These PPCs intend to articulate attributes of products, that are suitable for end users, to scientists, funding agencies and industry groups developing TB vaccine candidates intended for WHO pre-qualification and policy recommendations
Ann Ginsberg

12:47 - 12:59: The clinical development pipeline of new TB vaccinesThis presentation will summarise the progress in the clinical development pipeline of new tuberculosis (TB) vaccines and the prospect for their availability and use in countries that need them most. Considering that vaccines potentially offer a novel approach to combat emergence and transmission of anti-TB resistance, this session will also seek to inform the debate on the use of new vaccines in settings with high level of resistance.
Dereck Tait

12:59 - 13:11: A global roadmap for the research and development of new TB vaccinesThis presentation will share findings from the development of a global roadmap for the research and development of new tuberculosis (TB) vaccines, which was launched in 2020. The roadmap articulates elements of need across the clinical development, delivery and implementation of new TB vaccines in the form of research questions, as well as capacity needs with an end-to-end perspective. Crosscutting challenges and opportunities at the scientific, financial, policy, regulatory, manufacturing and access interface will be discussed in this presentation.
Frank Cobelens

13:11 - 13:23: Assessing the full value of new TB vaccines for decision-makingThe introduction of a new vaccine into national immunisation programmes often involves a trade off with investing in other vaccines or alternative strategies. As such, countries need broader information for assessing the comparative health and economic impact of new vaccines before implementation. I will share an update on progress in a project designed to assess the potential health and economic impact of new tuberculosis (TB) vaccines, using various vaccine characteristics and implementation scenarios. The intended goal is to proactively prepare evidence necessary for decision-making by countries, partners and institutions involved in new TB vaccine development and implementation.
Richard White

13:23 - 13:50: Q&A session

Loading...
Channel 3
OA-07-Moving away from isoniazid for TB preventive treatment
event_note
Loading...
query_builder 15:00 - 16:20 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-07-Moving away from isoniazid for TB preventive treatment
*Please scroll down for more information*


15:00 - 15:05: Introduction


15:05 - 15:13: OA-07-542-21-Safety of high-dose rifamycin for active and latent TB: a systematic review and meta-analysis There is an increasing interest in using rifamycins at higher doses to treat tuberculosis (TB). We performed a systematic review and meta-analysis to examine the safety and efficacy of rifamycin therapy for all patients with TB, by reviewing trials that compared daily administered, high-dose rifamycins to standard-dose rifamycins.

Omri A Arbiv

15:13 - 15:21: OA-07-543-21-Rifampicin maximum, early bactericidal activity not reached at 50 mg/kg The PanACEA HIGHRIF1 trial has recently evaluated the pharmacokinetics (PK) and early bactericidal activity (EBA) of rifampicin at 50 mg/kg. Our analysis focused on defining if earlier developed rifampicin PK and PK-pharmacodynamics models are applicable at a 50 mg/kg dose and if a maximal EBA is reached at 50 mg/kg rifampicin.

Budi O Susanto

15:21 - 15:29: OA-07-544-21-Treatment outcomes of people living with HIV on TB preventive therapy in Lusaka, Zambia Tuberculosis preventive therapy (TPT) has been proven to reduce incidence of TB among people living with HIV (PLHIV). The reduction in TB incidence is more significant in patients who complete a course of TPT compared to those who do not. Improving uptake of TPT among PLHIV is urgently required to reduce the TB burden.

Eugenia Mwamba

15:29 - 15:37: OA-07-545-21-A randomised controlled trial comparing two rifapentine-based short-course regimens for latent TB infection: 1HP vs 3HP 3HP is an attractive regimen for latent tuberculosis infection treatment. However, it is flawed in its systemic drug reactions. By reducing unit drug dosage, 1HP has been shown to have a favourable safety profile in HIV populations. The unanswered questions are the extrapolation of results to non-HIV population and direct comparison with 3HP regimen.

Jann-Yuan Wang

15:37 - 15:45: OA-07-546-21-Preparing for a short-course treatment regimen to prevent TB: catalysing procurement and policy to scale-up 3HP Unitaid funded the IMPAACT4TB project to scale-up 3HP in 12 countries. Work includes updating tuberculosis preventive therapy clinical guidelines, determining the scale of 3HP rollout per country, global 3HP price negotiations, support of generic manufacturers, and discussions with donors and governments to purchase 3HP.

Karin Turner

15:45 - 15:53: OA-07-547-21-Latent TB infection testing and treatment using shortened treatment regimen for contacts and secondary school children in Do Son district, Hai Phong, Viet Nam In 2019, Friends for International TB Relief, together with the Hai Phong TB Programme, implemented a community-wide, mobile screening campaign with integrated tuberculosis (TB) and latent TB infection (LTBI) testing and treatment. We describe the results of the LTBI testing and treatment activities, from screening to treatment completion.

Thuy Thu Thi Dong

15:53 - 16:01: OA-07-548-21-Impact of age on completion rate and systemic drug reaction of rifapentine-based weekly therapy for latent TB infection Under proper medical support and programmatic follow-up, 3HP can be of widespread use among populations of all ages, including the elders. Caution should be given for the high risk of systemic drug reaction in the middle-age population.

Hung-Ling Huang

16:01 - 16:20: Q&A


Loading...
Channel 3
SS-05-Leave no one behind: we can defeat COVID-19 and latent TB infection together
event_note
Loading...
query_builder 09:45 - 10:45 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Satellite session
mic English
SS-05-Leave no one behind: we can defeat COVID-19 and latent TB infection together
*Please scroll down for more information*
Organised by: QIAGEN
Global health experts are working to slow the COVID-19 pandemic – but responding to COVID-19 has also forced disruption of existing TB control programs around the globe. QIAGEN is committed to fighting COVID-19 and TB, developing innovative new testing solutions so that no one is left behind in the battle against pandemic lung diseases. Join our interactive symposium as we discuss QIAGEN's evolving solutions in two parts:
Part 1. QIAreach QuantiFERON-TB: A simple and accurate solution for decentralized TB infection screening
Currently in development, the QIAreach QuantiFERON-TB is a field-friendly, portable latent TB testing solution that will expand access to TB testing where it's needed the most. QIAGEN's assay development team will introduce the test and provide a scientific review of early performance data. This will be followed by first-hand experiences from ongoing trials of the test conducted in Zambia.

Part 2. Tackling TB and COVID-19 together: From centralized to decentralized testing
Stop TB and the WHO have highlighted the overlapping symptoms and risk groups shared by COVID-19 and TB. QIAGEN's Dr. Masae Kawamura will discuss shared disease etymologies and introduce QIAGEN's portfolio of cutting-edge solutions for both centralized and decentralized testing. Centralized solutions include: QuantiFERON-TB Gold Plus (TB) and QIAstat-Dx Respiratory SARS-CoV-2 Panel (SARS-CoV-2). Decentralized solutions include: QIAreach QuantiFERON-TB (TB), QIAreach Anti-SARS-CoV-2 Total (not available in all markets) and QIAreach SARS-CoV-2 Antigen Test (SARS-CoV-2).
Products and product claims may differ from country to country based on regulations and approvals. Contact your country representative for further details.
QIAreach QuantiFERON-TB and QIAreach SARS-CoV-2 Antigen are currently under development and coming soon. QIAreach QuantiFERON-TB is intended for high-TB-burden countries.

09:45 - 09:50: Introduction


09:50 - 09:57: QIAreach QuantiFERON-TB: a simple and accurate solution for decentralised TB infection screening Currently in development, the QIAreach QuantiFERON-TB is a field-friendly, portable latent tuberculosis (TB) testing solution that will expand access to TB testing where it's needed the most. QIAGEN's assay development team will introduce the test and provide a scientific review of early performance data. This will be followed by first-hand experiences from ongoing trials of the test conducted in Zambia.

Kwame Shanaube

09:57 - 10:11: Tackling TB and COVID-19 together: from centralised to decentralised testing Stop TB and the World Health Organization have highlighted the overlapping symptoms and risk groups shared by COVID-19 and tuberculosis (TB). QIAGEN's Dr. Masae Kawamura will discuss shared disease etymologies and introduce QIAGEN's portfolio of cutting-edge solutions for both centralised and decentralised testing. Centralised solutions include: QuantiFERON-TB Gold Plus (TB) and QIAstat-Dx Respiratory SARS-CoV-2 Panel (SARS-CoV-2). Decentralised solutions include: QIAreach QuantiFERON-TB (TB), QIAreach Anti-SARS-CoV-2 Total (not available in all markets) and QIAreach SARS-CoV-2 Antigen Test (SARS-CoV-2).

Masae Kawamura

Loading...
E-posters
EP18-Scaling up TB preventive therapy: it is about time!
event_note
Loading...
query_builder 10:00 - 11:00 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel E-poster session
mic English
EP18-Scaling up TB preventive therapy: it is about time!
*Please scroll down for more information*
All E-posters are accessible via the "E-posters" section of the conference platform until 30 November.

EP18-269-22-TB contact investigation in 17 municipalities of Uganda: bringing TB screening to the household via coalition with communitiesA half of tuberculosis (TB) patients in Uganda are missed, leading to continuous transmission in a system where case finding is passive. Community-led contact tracing (CI) was done to ensure early diagnosis and increasing access.  The results demonstrate that engaging community players in designing and implementing CI is effective. Community-led visiting is recommended.
Paddy Busulwa

EP18-270-22-Breakthrough TB among people living with HIV on isoniazid preventive therapy in ZambiaUse of isoniazid preventive therapy (IPT) has proven effective in the fight against latent tuberculosis (TB) infection and prevention of progression to active TB disease in people living with HIV. However, it has been observed that there are patients who develop TB while on IPT and usually in the first month of treatment.
Sarah Nyangu

EP18-271-22-TB preventive treatment: global targets and progress to dateAt the United Nations High-Level Meeting on tuberculosis (TB) in 2018, Member States committed to provide TB preventive treatment (TPT) to at least 30 million people between 2018 and 2022. In this presentation, we report global progress and recent trends on the main indicators for the programmatic management of TPT.
Saskia Den Boon

EP18-272-22-Understanding barriers to latent TB treatment in people living with HIV in Cambodia: results from the KAP survey and facility assessment from the OPTICAM studyTuberculosis preventive therapy (TPT) coverage for people living with HIV is low (<30%) in Cambodia. Barriers from healthcare workers and facilities to prescribing (TPT) were assessed, highlighting the need for targeted training on TPT focusing on systematic TB screening, side effects and drug-drug interactions. Improving TPT drug supplies is essential to access.
Jennifer Campbell

EP18-273-22-TB preventive therapy among contacts above 5 years in line with United Nations High-level mission commitment: the journey so far in NigeriaThe new policy to place >5years (including adults) on TB preventive therapy (TPT) was recently adopted by countries at the United Nations High-Level Meeting. Gradual uptake of TPT among this populations is observed. The best method to ensure increased completion rate among this population is the use of a shorter TPT regimen.
Obioma Chijioke-Akaniro

EP18-274-22-Prevalence of latent TB infection among household contacts of TB patients in a low-resource, high burden TB/HIV settingThe proportion of interferon gamma release assay (IGRA) positive household contacts (HHCs) in Uganda that would require tuberculosis preventive therapy was unknown. In early 2020, we conducted a cross-sectional survey among 352 HHCs in the four regions of the country. Of those that participated, 32.7% had a positive IGRA test result.
Simon Muchuro

EP18-275-22-TB preventive treatment cascade among household contacts of people with TB in Western Uganda (October 2017–September 2018)Household tuberculosis (TB) contacts are at high risk for TB infection. People living HIV and children aged <5 years are at high risk for progression to TB disease and prioritised for TB preventive treatment (TPT). We examined the TPT cascade among household contacts following TB contact tracing, including HIV testing.
Monita R. Patel

EP18-276-22-Good proportion of household contact children under 5 years were TB screened but not getting preventive therapy in two regions of EthiopiaThis study assessed the extent of household contact screening and tuberculosis (TB) preventive therapy implementation in two regions of Ethiopia - SNNPR and Addis Ababa. The contact investigation was conducted for contacts of bacteriologically-confirmed index pulmonary TB patients and the TB preventive therapy was provided for eligible children aged under 5 years.
Abdulsemed Umar

EP18-277-22-Implementation and scale-up of TB preventive treatment among people living with HIV, South Sudan, 2018–2020Tuberculosis preventive treatment (TPT) decreases tuberculosis incidence and mortality among people living with HIV (PLHIV). In South Sudan, staff from the Ministry of Health and the US President’s Emergency Plan for AIDS Relief overcame barriers to TPT implementation among PLHIV during 2018–2020.
Dennis Kenyi Lodiongo

Loading...
Channel 5
OA-15-TB preventive therapy: we need to do better
event_note
Loading...
query_builder 12:30 - 13:50 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-15-TB preventive therapy: we need to do better
*Please scroll down for more information*


12:30 - 12:35: Introduction


12:35 - 12:43: OA-15-592-22-Reaching at-risk groups with TB preventive therapy: building on commitments made at the United Nations High Level Meeting By September 2018, Uganda's tuberculosis preventive therapy (TPT) coverage was very low. Following high-level leadership and stakeholder engagement, procurement of commodities and the establishment of a strong accountability mechanism for TPT results, the country has surpassed its United Nations High-Level Meeting TPT enrollment target for people living with HIV, with a 90% completion rate. 

Stavia Turyahabwe

12:43 - 12:51: OA-15-594-22-Uptake of isoniazid preventive therapy among newly diagnosed people living with HIV initiating antiretroviral therapy in South Africa: a post-hoc analysis of a cluster randomised trial Fourteen clinics were randomised to standard of care or Quantiferon-gold in-tube test for diagnosis of TB infection in newly diagnosed people living with HIV in North West, South Africa. We present a post-hoc analysis of isoniazid preventive therapy uptake among participants who initiated antiretroviral treatment within 30 days of study enrolment.

Kate Shearer

12:51 - 12:59: OA-15-595-22-Systems approach to improve TB preventive therapy outcomes among people living with HIV in resource-limited settings: experiences from East-Central Uganda Tuberculosis preventive therapy outcomes have been suboptimal, especially in sub-Saharan Africa, due to a combination of health system and patient-level barriers. A health system approach to address logistical, health workforce, service delivery barriers and patient level- barriers, using the quality improvement methodology, is critical in ensuring good completion rates.

Rodrigo Nyinoburyo

12:59 - 13:07: OA-15-596-22-Increasing access to TB preventive treatment for children under-five in Democratic Republic of Congo: preliminary results We documented lessons learned from the implementation of household contact investigation of children 0-14 years old, in collaboration with a local civil society organisation, in 21 health facilities in Kinshasa, Democratic Republic of Congo (DRC)

VICKY ILUNGA

13:07 - 13:15: OA-15-597-22-Interferon-gamma cytokine concentration levels as a biomarker for recent infection with Mycobacterium tuberculosis in an African community setting Tuberculosis preventive therapy is prioritised for latently infected groups at high risk for active disease. In a cohort study design, we determined that concentrations of interferon-gamma could serve as a biomarker to discriminate individuals that are recently infected with Mycobacterium tuberculosis from remotely infected persons with similar TST reading.

Samuel Kirimunda

13:15 - 13:42: Q&A


Loading...
Channel 4
SS-07-Advancements in the TB diagnostics pipeline: FIND and NDWG annual  symposium
event_note
Loading...
query_builder 18:15 - 19:45 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Satellite session
mic English
SS-07-Advancements in the TB diagnostics pipeline: FIND and NDWG annual  symposium
*Please scroll down for more information*
Organised by: FIND and NDWG
Tuberculosis (TB) diagnostics are needed to detect exposure, diagnose disease and drug resistance, and to monitor improvement under treatment in both primary healthcare and laboratory settings. The Foundation for Innovative New Diagnostics (FIND) and the Stop TB  Partnership’s New Diagnostics Working Group (NDWG) bring to you the latest developments in TB diagnostics R&D. You will hear from leading  global experts on the advancements in the TB diagnostics pipeline, improvements in the detection of drug-resistant TB, next-generation  sequencing and the diagnosis of TB infection.

18:15 - 18:20: Introduction

Daniela Cirillo

18:20 - 18:40: TB diagnostics pipeline update: 2020 and beyond While we can accelerate progress, we cannot end the tuberculosis (TB) epidemic with the tools that we have today. We need rapid, and  affordable, non-sputum based tests for diagnosis or triage, accurate drug-susceptibility testing for critical medicines, and better tools to detect TB infection and testing for risk of progression to active disease. We are working with our partners and donors to make easy-to-use, robust, reliable and highly accurate tests a reality in routine clinical settings, particularly at the lower levels of care. Our R&D efforts are  focused on areas of critical unmet needs. Our session brings to you the most comprehensive update on the TB diagnostics pipeline in 2020  and beyond.

Morten Ruhwald

18:40 - 18:50: Recent advances in the diagnosis of drug-resistant TB The development and implementation of rapid molecular diagnostics for tuberculosis (TB) drug-susceptibility testing (DST) is critical to inform patient treatment and to prevent the emergence and spread of resistance. We report results from two recently completed  multicentre diagnostic accuracy studies: 1. the Xpert MTB/XDR assay (Cepheid, USA) for detecting resistance to isoniazid (INH), ethionamide (ETH), fluoroquinolones (FQs) and secondline injectables,amikacin (AMK), kanamycin (KAN), and capreomycin (CAP), and 2) the Molbio Truenat molecular diagnostic assays for detection of M.tb and RIF-resistance.

Adam Penn-Nicholson

18:50 - 19:00: Seq&Treat project: bringing next generation TB care to underserved communities Targeted next-generation sequencing (tNGS) has the potential to revolutionise tuberculosis (TB) drug-susceptibility testing (DST) as it can provide fast, accurate, safe and comprehensive results to inform clinical decision-making for current and upcoming drug-resistant TB  treatment regimens. The Unitaid-funded Seq&Treat project is designed to generate evidence and boost in-country capacity to support  global policy and adoption of end-to-end tNGS solutions for affordable, scalable and rapid TB DST. We report results from analytical validation  of three tNGS end-to-end solutions for detecting resistance to rifampicin (RIF), isoniazid (INH), ethionamide (ETH), fluoroquinolones (FQs),  second-line injectables (amikacin (AMK), kanamycin (KAN), and capreomycin (CAP), and pyrazinamide (PZA), among others.

Anita Suresh

19:00 - 19:10: Improving interpretation of pncA gene mutations for sequencing-based drug-susceptibility testing of pyrazinamid Pyrazinamide (PZA) is a key first line anti-tuberculosis (TB) drug, which is also recommended in regimens for treating isoniazid-resistant TB and for the completion of multidrug/rifampicin-resistant TB regimens. Because of the lack of appropriate infrastructure and technical difficulties,  phenotypic drug-susceptibility testing (pDST) for PZA is not carried out in many high-incidence countries and PZA is, therefore, used  empirically. The World Health Organization has concluded that sequencing of pncA may be the most reliable method to rule-in PZA resistance.  An increasing number of low-incidence countries are introducing routine next-generation sequencing from the first positive culture for all TB  cases. In this scenario, the question becomes how to interpret the pncA sequence data and whether pDST is still needed. This study  introduces a strategy to guide the initial treatment decision and a set of rules regarding confirmatory testing and the resolution of discordant  results.

Paolo Miotto

19:10 - 19:20: Advancing the TB prevention agenda Diagnosis of tuberculosis infection (TBI) remains challenging. To estimate the public health impact and cost-effectiveness  of screening for, and treating incipient TB (ITB), a deterministic, dynamictransmission model was developed by the New Diagnostics Working Group, assuming an ITB test which meets the World Health Organization target product profile. It predicted that, to be cost-effective, the cost of an ITB test will differ widely between countries,  depending on the costing approach and control strategy. Additionally, a systematic review was performed to synthesise current evidence on the  diagnostic value of novel in vivo specific skin tests for TBI compared to currently available in vitro IGRA tests and the PPD-TST. Test  performance of novel skin tests did not differ significantly to that reported for IGRA. Finally, a framework for evaluation of new  immunodiagnostic tests for TBI was developed to facilitate their standardised evaluation. The framework describes the principles to be  considered when evaluating new tests for TBI.

Alberto Matteelli

19:20 - 19:45: Q&A session


Loading...
Channel 1
SS-08-Role of policy and community in addressing Latent TB in India: leaving no one behind
event_note
Loading...
query_builder 09:45 - 10:45 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Satellite session
mic English
SS-08-Role of policy and community in addressing Latent TB in India: leaving no one behind
*Please scroll down for more information*
Organised by: KHPT, NTEP, USAID

Latent TB infection is a clinical condition defined by a positive tuberculin skin test in patients who have no clinical or radiological evidence of active disease. While India carries the highest burden of TB, with an estimated 2.69 million cases in 2018, there exist a high number of people with latent TB infection, with nearly 40% of the country’s population harboring this ‘silent infection’. In India, patients are not only burdened by their illness, but are concomitantly afflicted by tremendous social stigma due to being tested TB positive. This in turn has detrimental effects on the patients’ health and well-being, and is also one of the main drivers for negative health-seeking behavior. To this already dire situation are a large number of patients who are more at-risk of contracting TB, and less likely to seek or receive medical help for the same. In this light, we want to utilize a human-centric approach to best address the needs, create policy changes and provide access to treatment to the most vulnerable section of society, those who have been suffering in silence for far too long.


09:45 - 09:49: Introduction


09:49 - 10:06: Role of community in addressing LTBI in India

H.L Mohan

10:06 - 10:16: Leveraging community networks for addressing LTBI

Karuna Sagili

10:16 - 10:26: Role of Policy in addressing LTBI in India

Dalbir Singh

10:26 - 10:34: The key role of global partnerships: USAID and LTBI in India

Reuben Swamickan

10:34 - 10:37: Role of TB survivors in addressing LTBI in India

Sunitha David

Loading...
Processing. Please wait.
Loading...